Advanced Cell Technology is initiating a Phase I/II multicenter clinical trial using
FDA gives clearance to Advanced Cell Technology, for their First Clinical Trial to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Advanced Cell Technology is initiating a Phase I/II multicenter clinical trial using
Linear Mode
